HUTCHMED Reports Positive Phase III Sovleplenib Results in wAIHA
Hong Kong, Shanghai & Florham Park, N.J., June 12, 2026 HUTCHMED (China) Limited announced positive results from the Phase...
Syk inhibitor
Advertisement
UCB and Biogen Report Positive Phase 3 Lupus Results for Dapirolizumab Pegol in The Lancet
BRUSSELS, Belgium and CAMBRIDGE, Mass., June 1, 2026 UCB and Biogen announced the publication of full Phase 3 PHOENYCS...
Agios Expands Rare Hematology Portfolio with Global Cevidoplenib Licensing Deal
CAMBRIDGE, Mass., June 1, 2026 Agios Pharmaceuticals has entered an exclusive global licensing agreement with South Korea-based Oscotec to...
HUTCHMED Advances Sovleplenib NDA for wAIHA in China
HONG KONG, SHANGHAI & FLORHAM PARK, N.J., April 29, 2026 HUTCHMED (China) Limited has announced that the New Drug...
Advertisement
